SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Genaera Corp
An SI Board Since August 2003
Posts SubjectMarks Bans Symbol
96 12 0 GENR
Emcee:  Matrix_Man Type:  Unmoderated
Introduction Market Data Compact
Genaera Corporation is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. The Company's research and development efforts are focused on anti-angiogenesis and respiratory diseases. Squalamine is a naturally occurring water-soluble small molecule and the Company's lead anti-angiogenic development candidate. The Company's development efforts for this anti-angiogenic molecule are focused on serious diseases, including age-related macular degeneration and cancer. It also maintains a respiratory product development program designed to discover and develop treatment alternatives for respiratory diseases. Through genomics research, Genaera has concentrated its efforts on determining the manner in which genes specifically impact respiratory disease. Its first genomics-based program is focused on the development of a blocking antibody to interleukin-9 to treat a root cause of asthma.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
96What GENR management should do: siliconinvestor.comDewDiligence_on_SI-12/17/2007
95MACM inks deal with GENR: siliconinvestor.com These two crappy companies deserDewDiligence_on_SI-10/3/2007
94Several months ago, but a reverse split will get the price up.technetium-4/12/2007
93Thought the info regarding reducing the staff by 30% to focus on obesity and astlexi2004-4/11/2007
92Oh well. Never mind.tom pope-4/10/2007
91<i>Makes sense. The age group at risk for macular degeneration.</i> DewDiligence_on_SI-4/10/2007
90Makes sense. The age group at risk for macular degeneration.tom pope-4/10/2007
89The median age of the GENR directors up for election is 71 years: investorshub.DewDiligence_on_SI-4/10/2007
88Evizon R.I.P.? investorshub.com The scam unravels.DewDiligence_on_SI-9/26/2006
87In the recent financing, GENR had to reimburse the placement agents for their ouDewDiligence_on_SI-7/3/2006
86Lucentis approved by FDA: The myriad posters throughout message-board cyberspacDewDiligence_on_SI-6/30/2006
85New 3-year low today. It looks like the bogus Dawson James report wasn’t especDewDiligence_on_SI-6/28/2006
84Hi, nice patent news today.Shares trading higher pre mkt this morning.Love to seBenny-Rubin-6/23/2006
83That’s my point exactly: they are a placement agent, not a research firm with boDewDiligence_on_SI-5/25/2006
82Who is Dawson James Securities?? Investment Banking Rankings Top 10 Agents By Njstrohs-5/25/2006
81Who the heck is Dawson James? Are they one of those firms that publishes “researDewDiligence_on_SI-5/18/2006
80NSTITUTIONAL RESEARCH Healthcare & Biotechnology UPDATE REPORT Dawsonjstrohs-5/17/2006
79Points to consider: investorshub.comDewDiligence_on_SI-11/11/2005
78Musings on GENR’s Rodman & Renshaw talk from 11/7/05: investorshub.comDewDiligence_on_SI-11/10/2005
77Cautionary language on patient enrollment from GENR’s 10Q: investorshub.comDewDiligence_on_SI-11/9/2005
76Genaera Presents Positive Preliminary Clinical Results for EVIZON(TM) for TreatmDoc Bones-10/19/2005
75CEO, Levitt, 'resigns': investorshub.comDewDiligence_on_SI-10/18/2005
74Dave et al: I see the market for AMD treatments proceeding in three steps: 1. DewDiligence_on_SI-10/12/2005
73Dave: you make some good points, but they don’t alter the fact that today’s dataDewDiligence_on_SI-10/11/2005
72Dew, in response to your Yahoo post on visual outcomes c Wet Mac Degen. Some weDave Mordis-10/11/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News